Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Jul 03, 2015 2:04pm

93 Views

Post# 23890192

RE:RE:RE:LOOK FAMILIAR

No surprise that BP is doing deals in China. The economics are favourable. The culture in their developed areas is scientifically advanced and we are all experiencing how successful the Chinese have taken over North American manufacturing in every sector you can imagine.

Resverlogix is just tapping in to what Apple, Google, Nike and thousands of North American companies started doing 25 years ago and I am thrilled.

Good things are coming sooner than later.
Cheers
Toinv :)

Bullboard Posts

Drilling company poised to capitalize on market conditions